Home Newsfeeds JP Morgan Downgrades Bright Health Gr to Underweight

JP Morgan Downgrades Bright Health Gr to Underweight

JP Morgan analyst Lisa Gill downgrades Bright Health Gr (NYSE:BHG) from Neutral to Underweight.

byBenzinga Newsdesk

October 11, 2022

1 minute read

JP Morgan analyst Lisa Gill downgrades Bright Health Gr (NYSE:BHG) from Neutral to Underweight.

IPOs
News

Iron Horse Acquisitions Corp. Announces Pricing Of $61M Initial Public Offering Of 6.1M Units At A Price Of $10/Unit

By Benzinga Newsdesk

December 27, 10:09 AM

Iron Horse Acquisitions Corp. (NASDAQ:IROHU, the "Company")))) announced today that it priced its initial public offering of 6,100,000 units at $10.00 per unit. The units are expected to be listed on the Nasdaq Global

IROHU

CORRECTION: Lovesac Co Expects Q1 Net Sales of $126M-$132M Vs $147.53M Est and EPS of $(0.84)-$(1.03) Vs $(0.15) Est, FY25 Net Sales of $700M-$770M Vs $765.38M Est and EPS of $1.06-$1.59 Vs $2.15 Est

By Benzinga Newsdesk

April 11, 10:45 AM

The Company expects the following for the full year of fiscal 2025: Net sales in the range of $700 million to $770 million. Adjusted EBITDA1 in the range of $46 million to $60 million. Net income in the range of $18

LOVE

Kamada Announces Submission Of Application To US FDA To Manufacture CYTOGAM At Company’s Facility In Israel

By Benzinga Newsdesk

January 4, 8:01 AM

FDA Approval Currently Expected by Mid-2023 Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021, with Gross Margins Over 50% Ability to Manufacture CYTOGAM at Kamada's Facility to

KMDA

UBS Maintains Buy on MongoDB, Raises Price Target to $215

By Benzinga Newsdesk

December 7, 7:49 AM

UBS analyst Karl Keirstead maintains MongoDB (NASDAQ:MDB) with a Buy and raises the price target from $200 to $215.

MDB

JP Morgan Downgrades Bright Health Gr to Underweight

Related Posts

Iron Horse Acquisitions Corp. Announces Pricing Of $61M Initial Public Offering Of 6.1M Units At A Price Of $10/Unit

CORRECTION: Lovesac Co Expects Q1 Net Sales of $126M-$132M Vs $147.53M Est and EPS of $(0.84)-$(1.03) Vs $(0.15) Est, FY25 Net Sales of $700M-$770M Vs $765.38M Est and EPS of $1.06-$1.59 Vs $2.15 Est

Kamada Announces Submission Of Application To US FDA To Manufacture CYTOGAM At Company’s Facility In Israel

UBS Maintains Buy on MongoDB, Raises Price Target to $215